The highly sensitive and artificial biochemical assays that enable high-throughput screening are vulnerable to artifact-generating compounds that occur in drug screening collections. An investigation of known aggregator compounds and amyloid fibrillization inhibitors suggests that such inhibitors operate via a nonspecific mechanism in a well-used assay of amyloid fibrillization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Feng, B.Y. et al. Nat. Chem. Biol. 4, 197–199 (2008).
Rishton, G.M. Drug Discov. Today 2, 382–384 (1997).
Rishton, G.M. Drug Discov. Today 8, 86–96 (2003).
Roche, O. et al. J. Med. Chem. 45, 137–142 (2002).
Shoichet, B.K. et al. J. Med. Chem. 45, 1712–1722 (2002).
Shoichet, B.K. et al. J. Med. Chem. 46, 4265–4272 (2003).
Shoichet, B.K. et al. J. Med. Chem. 46, 1478–1483 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rishton, G. Aggregator compounds confound amyloid fibrillization assay. Nat Chem Biol 4, 159–160 (2008). https://doi.org/10.1038/nchembio0308-159
Issue Date:
DOI: https://doi.org/10.1038/nchembio0308-159
This article is cited by
-
A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo
Neurotherapeutics (2012)